Procept BioRobotics $PRCT presents a compelling setup for investors. The company operates a classic "razor and blade" business model, driving high-margin recurring revenue through its robotic surgical systems

Despite the stock’s recent drawdown, fundamentals remain robust with annual growth sustaining near 30%

Confidence in the recovery is signaled by a recent $10.5M insider purchase from a company director. However, the investment case is clouded by excessive SBC. While bulls often dismiss SBC as a necessary cost for talent, the current levels at Procept feel less like retention and more like management gluttony, a red flag for shareholders concerned about dilution